126 related articles for article (PubMed ID: 15566511)
1. Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy.
Iwasaki Y; Takaguchi K; Ikeda H; Makino Y; Araki Y; Ando M; Kobashi H; Kobatake T; Tanaka R; Tomita M; Senoh T; Kawaguchi M; Shimoe T; Manabe K; Kita K; Shimamura J; Sakaguchi K; Shiratori Y
Liver Int; 2004 Dec; 24(6):603-10. PubMed ID: 15566511
[TBL] [Abstract][Full Text] [Related]
2. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
[TBL] [Abstract][Full Text] [Related]
3. Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C.
Hasegawa I; Orito E; Tanaka Y; Hirashima N; Sakakibara K; Sakurai M; Suzuki S; Sugauchi F; Ohno T; Ueda R; Mizokami M
Liver Int; 2005 Apr; 25(2):247-53. PubMed ID: 15780046
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
[TBL] [Abstract][Full Text] [Related]
5. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Fukui H; Inui Y; Hijioka T; Inada M; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Hayashi E; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1186-95. PubMed ID: 24321207
[TBL] [Abstract][Full Text] [Related]
6. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
Scand J Gastroenterol; 2005 Jun; 40(6):688-96. PubMed ID: 16036529
[TBL] [Abstract][Full Text] [Related]
8. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
Hung CH; Lee CM; Wang JH; Hu TH; Chen CH; Lin CY; Lu SN
Int J Cancer; 2011 May; 128(10):2344-52. PubMed ID: 20669224
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.
Kasahara A; Hayashi N; Mochizuki K; Takayanagi M; Yoshioka K; Kakumu S; Iijima A; Urushihara A; Kiyosawa K; Okuda M; Hino K; Okita K
Hepatology; 1998 May; 27(5):1394-402. PubMed ID: 9581697
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
[TBL] [Abstract][Full Text] [Related]
11. Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma.
Mahmood S; Niiyama G; Kamei A; Izumi A; Nakata K; Ikeda H; Suehiro M; Kawanaka M; Togawa K; Yamada G
Liver Int; 2005 Apr; 25(2):220-5. PubMed ID: 15780042
[TBL] [Abstract][Full Text] [Related]
12. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis.
Aizawa Y; Shibamoto Y; Takagi I; Zeniya M; Toda G
Cancer; 2000 Jul; 89(1):53-9. PubMed ID: 10897000
[TBL] [Abstract][Full Text] [Related]
13. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.
Asahina Y; Tsuchiya K; Nishimura T; Muraoka M; Suzuki Y; Tamaki N; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nakagawa M; Kakinuma S; Watanabe M; Izumi N
Hepatology; 2013 Oct; 58(4):1253-62. PubMed ID: 23564522
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
[TBL] [Abstract][Full Text] [Related]
15. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.
Arase Y; Ikeda K; Tsubota A; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2004; 47(6):355-61. PubMed ID: 15564748
[TBL] [Abstract][Full Text] [Related]
16. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C.
Arase Y; Kobayashi M; Suzuki F; Suzuki Y; Kawamura Y; Akuta N; Kobayashi M; Sezaki H; Saito S; Hosaka T; Ikeda K; Kumada H; Kobayashi T
Hepatology; 2013 Mar; 57(3):964-73. PubMed ID: 22991257
[TBL] [Abstract][Full Text] [Related]
17. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
Yoshida H; Shiratori Y; Moriyama M; Arakawa Y; Ide T; Sata M; Inoue O; Yano M; Tanaka M; Fujiyama S; Nishiguchi S; Kuroki T; Imazeki F; Yokosuka O; Kinoyama S; Yamada G; Omata M
Ann Intern Med; 1999 Aug; 131(3):174-81. PubMed ID: 10428733
[TBL] [Abstract][Full Text] [Related]
18. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection.
Asahina Y; Tsuchiya K; Tamaki N; Hirayama I; Tanaka T; Sato M; Yasui Y; Hosokawa T; Ueda K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Izumi N
Hepatology; 2010 Aug; 52(2):518-27. PubMed ID: 20683951
[TBL] [Abstract][Full Text] [Related]
19. Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy.
Narita Y; Genda T; Tsuzura H; Sato S; Kanemitsu Y; Ishikawa S; Kikuchi T; Hirano K; Iijima K; Wada R; Ichida T
J Gastroenterol Hepatol; 2014 Jan; 29(1):137-43. PubMed ID: 24117602
[TBL] [Abstract][Full Text] [Related]
20. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
Imai Y; Tamura S; Tanaka H; Hiramatsu N; Kiso S; Doi Y; Inada M; Nagase T; Kitada T; Imanaka K; Fukuda K; Takehara T; Kasahara A; Hayashi N
J Viral Hepat; 2010 Mar; 17(3):185-91. PubMed ID: 19709362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
